FDC Limited
FDC (Fairdeal Corporation) Ltd Limited (found in 1936) is among India‚Äôs leading fully integrated pharmaceutical companies. The Company is a pioneer in the manufacture of specialized formulations, and among the world‚Äôs foremost manufacturers and marketers of Oral Rehydration Salts (ORS). Some of FDC‚Äôs leading brands in India include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zathrin, Zipod, Cotaryl and…
What FDC files
- Others43
- Updates20
- Important13
- Board Meeting10
- Dividend/Bonus6
- Results2
FDC secured an interim stay from Delhi HC on FSSAI's mislabeling notice for 'electrolyte' products. The company has 8 months to update labels and clear stock. This development has no material financial or operational impact.
FDC's subsidiary, FDC International, secured UK marketing authorization for Atropine 1.0% eye drops. This key business development opens a new market opportunity for the product in the United Kingdom.
FDC's Q1 FY27 revenue rose 3% to Rs 668 Cr, with PAT up 9.2% to Rs 132 Cr. Strong international formulation sales (+74.2% Y-o-Y), driven by the US business (+118.4%), offset subdued domestic and API segments. The company secured US FDA approval for Cefixime.
Food Safety Officials seized FDC's 'Enerzal' stock for alleged misbranding, taking samples for examination. The company plans legal recourse. Management states there is no material financial or operational impact currently, and business continues as usual.
FDC posted robust Q4 FY26 results: Revenue surged 18.9% to 585 Cr, and PAT jumped 167.4% to 103 Cr, boosted by strong Export Formulations and API growth, including a US business turnaround. The company also received U.S. FDA approval for Fluconazole Tablets.